Osteosarcoma - mifamurtide (TA235)
NICE recommends mifamurtide as a possible treatment for some children, adolescents and young adults with osteosarcoma.
Who can have mifamurtide?
Children, adolescents and young adults should be able to have mifamurtide if:
- their tumour is high-grade and non-metastatic and
- they have had an operation to remove the tumour and
- they are also having chemotherapy with multiple drugs.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended mifamurtide because more people are cured if they have mifamurtide as well as chemotherapy, and the cost was justified by the benefits it provided.
This page was last updated: 23 January 2014
- Web format
- Full Guidance (PDF)
- TA235 Mifamurtide ar gyfer osteosarcoma: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.